You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 16, 2025

TRUMENBA Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: TRUMENBA
High Confidence Patents:0
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for TRUMENBA
Recent Clinical Trials for TRUMENBA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Sanofi Pasteur, a Sanofi CompanyPhase 1/Phase 2

See all TRUMENBA clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TRUMENBA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TRUMENBA Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for TRUMENBA Derived from Patent Text Search

These patents were obtained by searching patent claims

Market Dynamics and Financial Trajectory for TRUMENBA

Introduction to TRUMENBA

TRUMENBA is a meningococcal group B vaccine developed by Pfizer, Inc. It is designed to protect individuals against invasive meningococcal disease (IMD) caused by serogroup B, a leading cause of meningitis and sepsis.

Market Size and Growth

The global meningococcal vaccines market, which includes TRUMENBA, is projected to experience significant growth. As of 2022, the global meningococcal vaccines market was valued at USD 3.28 billion and is expected to grow at a compound annual growth rate (CAGR) of 6.0% from 2023 to 2030[1].

Segmentation and Dominance

TRUMENBA is part of the serotype B segment, which dominated the global market with a revenue share of 36.3% in 2022. This dominance is attributed to the strong presence of vaccines like TRUMENBA and Bexsero, as well as the increasing disease burden of MenB worldwide, particularly in North America and Europe[1].

Regional Performance

North America, led by the U.S. and Canada, dominates the meningococcal vaccines market, including TRUMENBA, with a market share of 57.0% in 2022. This is driven by favorable government recommendations, high R&D investments, and a well-developed healthcare structure in the region[1].

Sales Channels

The public sales channel segment holds the largest market share, accounting for 69.4% in 2022. This is due to the inclusion of major meningococcal vaccine brands, such as TRUMENBA, in immunization programs funded by governments[1].

Regulatory Approvals and Market Expansion

TRUMENBA has received significant regulatory approvals that have expanded its market reach. For instance, in May 2017, the European Commission approved TRUMENBA for individuals aged 10 and above, and in July 2017, it was approved in the U.K. for the same age group[1].

Clinical Data and Immunogenicity

Phase 3 clinical trials for TRUMENBA have demonstrated its immunogenicity, showing that the vaccine elicits a protective immune response against diverse meningococcal group B strains as a three-dose series[3].

Financial Performance of Pfizer

While TRUMENBA's specific financial performance is not isolated in Pfizer's reports, the overall biopharmaceutical segment of Pfizer, which includes TRUMENBA, has shown significant growth. In 2022, Pfizer's global biopharmaceuticals business revenues were substantial, although the company's overall revenues were heavily influenced by COVID-19 products like Comirnaty and Paxlovid[5].

Growth Drivers

Several factors drive the growth of TRUMENBA:

  • Increasing Awareness: Growing awareness about meningococcal disease and the importance of vaccination.
  • Government Initiatives: Government-funded immunization programs that include TRUMENBA.
  • R&D Activities: Continuous research and development to improve vaccine efficacy and expand protection against other serotypes[1].

Challenges and Risks

Despite the positive outlook, there are challenges and risks associated with TRUMENBA:

  • Regulatory Uncertainties: Uncertainties regarding recommendations from vaccine technical committees and public health authorities.
  • Commercial Success: Risks related to the commercial success of TRUMENBA, including competition from other vaccines.
  • Clinical Trial Outcomes: The possibility of unfavorable clinical trial results or new clinical data that could impact the vaccine's approval and adoption[3].

Market Impact of COVID-19

The COVID-19 pandemic had a temporary negative impact on the meningococcal vaccines market, including TRUMENBA, with net sales declining in 2020. However, the market has since recovered, with positive year-over-year growth observed in 2022 due to increased government initiatives and awareness campaigns[1].

Future Outlook

TRUMENBA is expected to continue growing at the fastest rate among meningococcal vaccines due to its increasing marketing approvals and growing awareness about the disease. The vaccine's inclusion in public immunization programs and ongoing research to develop pentavalent vaccines further support its market growth[1].

Key Takeaways

  • TRUMENBA is a significant player in the meningococcal vaccines market, driven by its strong presence in the serotype B segment.
  • The vaccine has received critical regulatory approvals, expanding its market reach.
  • Government initiatives, increasing awareness, and R&D activities are key growth drivers.
  • Despite challenges, TRUMENBA is expected to continue its growth trajectory.

FAQs

What is TRUMENBA?

TRUMENBA is a meningococcal group B vaccine developed by Pfizer, Inc., designed to protect against invasive meningococcal disease caused by serogroup B.

What is the current market size of the meningococcal vaccines market?

As of 2022, the global meningococcal vaccines market was valued at USD 3.28 billion[1].

What is the projected growth rate of the meningococcal vaccines market?

The market is expected to grow at a CAGR of 6.0% from 2023 to 2030[1].

Which region dominates the market for TRUMENBA?

North America, particularly the U.S. and Canada, dominates the market with a 57.0% share in 2022[1].

What are the main drivers of TRUMENBA's market growth?

Key drivers include increasing awareness, government initiatives, and ongoing R&D activities[1].

How has the COVID-19 pandemic affected the market for TRUMENBA?

The pandemic led to a temporary decline in 2020, but the market has since recovered with positive year-over-year growth in 2022[1].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.